Cell Rep: Coronavirus is less likely to trigger antibody cross immunoprotection effects

2020 May 19 News / BioValley BIOON / --- In a recent study, researchers reported that generate patient infected with SARS-CoV or SARS-CoV-2 is an antibody may be combined with another coronavirus, but cross-reactive antibodies, at least in vitro cell culture experiments no cross protectionRelated results on May 17 published in the "CellReports" magazineIt is not clear whether such antibodies provide cross-protection or lead to disease progression in humansThese findings suggest that more research is needed to identify for the induction of cross-protective immune response is essential viral componentsCo-senior study authorChrisMok University of Hong Kong, said: "As the coronavirus outbreak in the future may continue to pose a threat to global health, and therefore have to consider the possibility of the development of cross-protective vaccines against a variety of coronavirus Although the current findingslimited, but our findings suggest that the human immune repertoire may not generally produce extensive cross against coronavirus neutralizing antibody "
(source: Www.pixabay.com)from late 2002-2003 in the world there are more than 8,000 people suffering from severe acute respiratory syndrome (SARS), resulting in 700 deathsCause of this outbreak of the virus known as SARS-CoV, the virus and the popular genome sequence of the SARS-CoV-2 has about 80% identityOn the other hand, two mechanisms coronavirus infection caused by the invasion of host cells are also similarPast studies have shown, can be combined with RBD protective antibodies against the SARS-CoVBut for the SARS-CoV-2 antibody response induced by infection is poorly understoodIt is unclear how SARS-CoV infection affect antibody response to SARS-CoV-2, and vice versaIn-depth understanding of these issues, we can guide the development of SARS-CoV-2 vaccineTo answer this question, the researchers analyzed blood samples from symptoms between 2-22 days after the onset collected from SARS-CoV-2 infection in patients with 15 cases in Hong Kong Blood samples as compared to healthy controls, 11 days after the onset of symptoms, or later from the patient to collect a sample of five capable of binding with the RBD SARS-CoV-2 and SARS-CoV S protein antibody and the other moiety researchers also analyzed blood samples from SARS-CoV infection after 3-6 months from seven patients gathered there Compared with healthy control subjects blood samples, collected from a patient, where the sample is capable of binding with the RBD of SARS-CoV-2 and other portions of the active protein S antibody Taken together, these findings suggest that, where a certain kind of coronavirus infection induces production of antibodies capable of the S protein with another subtype coronavirus RBD binding region and a non-RBD cell culture experiments, the researchers next tested whether SARS-CoV-2 infection induces SARS-CoV-2-specific neutralizing antibodies The results showed that all 11 blood samples collected 12 days after the onset of symptoms or have neutralizing antibodies against SARS-CoV-2's But only one blood sample with anti-SARS-CoV cross-neutralizing antibodies and this response is very weak Similarly, the five blood samples of patients infected with SARS-CoV has neutralizing antibodies against the virus, but no one can cross-neutralizing SARS-CoV-2 (Biovalley Bioon.com) Information Source: Coronavirusesdonotreadilyinducecross-protectiveantibodyresponses Original source: HuibinLvetal, Cross-reactiveantibodyresponsebetweenSARS-CoV-2andSARS- CoVinfections, CellReports (2020) .DOI: 10.1016 / j.celrep.2020.107725